GPCB(cant make typo errors on this board) - On reading the briefing docs, I find it inexplicable that the market is trading these shares down. By ODAC/Pazdur's own rules, this is a very strong package for approval.
The data clearly shows that the drug is doing something. Whatever little can be seen from interim OS and subset OS are quite favourable. If the FDA delays this, SPA and AC meetings will indeed become a joke.
Market Data 
Markets 
AI
